These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25921526)

  • 1. An oncogenic role for alternative NF-κB signaling in DLBCL revealed upon deregulated BCL6 expression.
    Zhang B; Calado DP; Wang Z; Fröhler S; Köchert K; Qian Y; Koralov SB; Schmidt-Supprian M; Sasaki Y; Unitt C; Rodig S; Chen W; Dalla-Favera R; Alt FW; Pasqualucci L; Rajewsky K
    Cell Rep; 2015 May; 11(5):715-26. PubMed ID: 25921526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
    Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
    Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma.
    Li MY; Chong LC; Duns G; Lytle A; Woolcock B; Jiang A; Telenius A; Ben-Neriah S; Nawaz W; Slack GW; Elisia I; Viganò E; Aoki T; Healy S; Krystal G; Venturutti L; Scott DW; Steidl C
    Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2320421121. PubMed ID: 38662551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
    Kim SW; Oleksyn DW; Rossi RM; Jordan CT; Sanz I; Chen L; Zhao J
    Blood; 2008 Feb; 111(3):1644-53. PubMed ID: 18025152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
    Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression.
    Lossos IS
    Cancer Cell; 2007 Sep; 12(3):189-91. PubMed ID: 17785200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.
    Saito M; Gao J; Basso K; Kitagawa Y; Smith PM; Bhagat G; Pernis A; Pasqualucci L; Dalla-Favera R
    Cancer Cell; 2007 Sep; 12(3):280-92. PubMed ID: 17785208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
    Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
    Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
    Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
    Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic inactivation of TRAF3 in canine and human B-cell lymphoma.
    Bushell KR; Kim Y; Chan FC; Ben-Neriah S; Jenks A; Alcaide M; Fornika D; Grande BM; Arthur S; Gascoyne RD; Steidl C; Morin RD
    Blood; 2015 Feb; 125(6):999-1005. PubMed ID: 25468570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
    Li L; Xu-Monette ZY; Ok CY; Tzankov A; Manyam GC; Sun R; Visco C; Zhang M; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Wang J; Parsons BM; Winter JN; Piris MA; Pham LV; Medeiros LJ; Young KH
    Oncotarget; 2015 Sep; 6(27):23157-80. PubMed ID: 26324762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
    Ok CY; Xu-Monette ZY; Li L; Manyam GC; Montes-Moreno S; Tzankov A; Visco C; Dybkær K; Routbort MJ; Zhang L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Rao H; Møller MB; Winter JN; Piris MA; Wang SA; Medeiros LJ; Young KH
    Mod Pathol; 2015 Sep; 28(9):1202-13. PubMed ID: 26111978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
    Eluard B; Nuan-Aliman S; Faumont N; Collares D; Bordereaux D; Montagne A; Martins I; Cagnard N; Caly M; Taoui O; Lordello L; Lehmann-Che J; Tesson B; Martinez-Climent JA; Copie-Bergman C; Haioun C; Tilly H; Bonsang B; Vincent-Salomon A; Jais JP; Jardin F; Leroy K; Maiuri MC; Kroemer G; Molina TJ; Feuillard J; Baud V
    Blood; 2022 Jan; 139(3):384-398. PubMed ID: 34232979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21).
    Kuo SH; Tsai HJ; Lin CW; Yeh KH; Lee HW; Wei MF; Shun CT; Wu MS; Hsu PN; Chen LT; Cheng AL
    J Pathol; 2017 Feb; 241(3):420-433. PubMed ID: 27873317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
    Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
    Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
    Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
    Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
    Davis RE; Brown KD; Siebenlist U; Staudt LM
    J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.